Reversal of erythema multiforme major with cyclophosphamide and prednisone

被引:11
作者
Eastham, JH
Segal, JL
Gomez, MF
Cole, GW
机构
[1] VET AFFAIRS MED CTR,SERV PHARM,LONG BEACH,CA 90822
[2] VET AFFAIRS MED CTR,DEPT MED,LONG BEACH,CA 90822
[3] VET AFFAIRS MED CTR,DERMATOL SERV,LONG BEACH,CA 90822
关键词
D O I
10.1177/106002809603000607
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
OBJECTIVE To report a case of erythema multiforme (EM) major treated with cyclophosphamide and prednisone. SETTING: General medicine and dermatology consult services, Department of Veterans Affairs Medical Center. CASE SUMMARY: A 44 year-old man with C4-C5 quadriplegia developed a skin reaction characterized by a painful, generalized maculopapular rash, bullae, ulceronecrotic lesions, and mucosal and epidermal sloughing after taking trimethoprim/sulfamethoxazole. The patient was treated with intravenous cyclophosphamide 150 mg infused over 1 hour every 24 hours and oral prednisone 15 mg every 6 hours. After tow doses of cyclophosphamide, formation of bullae and epidermal sloughing had ceased, and the erythema was markedly diminished. Cyclophosphamide was discontinued before the third dose because of evolving leukopenia. Prednisone therapy was continued until the patient was discharged on hospital day 5, at which time the dosage was tapered. DISCUSSION: Cyclophosphamide has been used extensively for other dermatologic reactions. Relief of pain and regression of the lesions in our patient occurred more quickly than anticipated. CONCLUSION: Treatment of EM major with cyclophosphamide combined wit prednisone appeared to be highly successful in this patient. Cyclophosphamide may be an effective, empiric initial treatment in reversing EM major.
引用
收藏
页码:606 / 607
页数:2
相关论文
共 8 条
[1]  
FRITSCH PO, 1993, DEMATOLOGY GEN MED, P592
[2]   CHARACTERISTICS OF TOXIC EPIDERMAL NECROLYSIS IN PATIENTS UNDERGOING LONG-TERM GLUCOCORTICOID THERAPY [J].
GUIBAL, F ;
BASTUJIGARIN, S ;
CHOSIDOW, O ;
SAIAG, P ;
REVUZ, J ;
ROUJEAU, JC .
ARCHIVES OF DERMATOLOGY, 1995, 131 (06) :669-672
[3]   IMPROVED BURN CENTER SURVIVAL OF PATIENTS WITH TOXIC EPIDERMAL NECROLYSIS MANAGED WITHOUT CORTICOSTEROIDS [J].
HALEBIAN, PH ;
CORDER, VJ ;
MADDEN, MR ;
FINKLESTEIN, JL ;
SHIRES, GT .
ANNALS OF SURGERY, 1986, 204 (05) :503-512
[4]   EFFICACY OF CYCLOPHOSPHAMIDE IN TOXIC EPIDERMAL NECROLYSIS - CLINICAL AND PATHOPHYSIOLOGIC ASPECTS [J].
HENG, MCY ;
ALLEN, SG .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1991, 25 (05) :778-786
[5]   IMMUNOSUPPRESSIVE AGENTS IN DERMATOLOGY [J].
HO, VC ;
ZLOTY, DM .
DERMATOLOGIC CLINICS, 1993, 11 (01) :73-85
[6]  
HUFF JC, 1983, J AM ACAD DERMATOL, V8, P763
[7]  
Kim PS, 1983, J BURN CARE REHABIL, V4, P91
[8]  
RASMUSSEN JE, 1976, BRIT J DERMATOL, V95, P181, DOI 10.1111/j.1365-2133.1976.tb00824.x